IL5 and Nasal polyposis: In fact, treatment with anti-IL5 (mepolizumab) has shown a reduction in both nasal polyp and blood eosinophils, and a significant improvement in CRSwNP patients, resulting in better prognosis (Bachert et al., 2017).